LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Ouvert

SecteurSoins de santé

1.88 -4.08

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.8399999999999999

Max

1.98

Chiffres clés
By Trading Economics
Revenu	2.6M -39M
Employés	150
EBITDA	-1.4M -39M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+335.5% upside

Dividendes
By Dow Jones
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	225M 787M
Ouverture précédente	5.96
Clôture précédente	1.88

Sentiment de l'Actualité

By Acuity

35%

65%

98 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.18 / 1.69 Support & Résistance

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 mai 2026, 23:10 UTC

Actions en Tendance

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principaux Mouvements du Marché

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Résultats

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Résultats

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Résultats

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Résultats

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Acquisitions, Fusions, Rachats

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Acquisitions, Fusions, Rachats

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Acquisitions, Fusions, Rachats

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Vinci Buys Canada's Modern Group of Companies

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

335.5% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 335.5%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.18 / 1.69Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

98 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.